Deriving Drug Discovery Value from Large-Scale Genetic Bioresources Proceedings of a Workshop (2016) / Chapter Skim
Currently Skimming:
Appendix B: Speaker Biographical Sketches
Appendix B: Speaker Biographical Sketches
Pages 71-84
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 71... ...
He is particularly interested in informatics methods for advancing pharmacogenomics, the study of how human genetic variation affects drug response. Other work focuses on the analysis of functional sites within macromolecules with an emphasis on understanding the action, interaction, and adverse events of drugs.
|
From page 72... ...
In his current role, Dr. Baras co-leads Regeneron's broad research programs in human genetics, with responsibility for overall scientific strategy, ensuring operational excellence, and establishing critical research collaborations, encompassing large-scale sequencing and genetic analysis, such as with the Geisinger Health System (GHS)
|
From page 73... ...
His current interests are (1) using X-ray structures of novel human proteins to generate small molecule inhibitors, screening in human cells to identify novel targets for drug discovery, and then developing clinical candidates for evaluation in patients, precompetitively; (2)
|
From page 74... ...
Human Genetics has revealed rare and common variants that can be directly targeted by drugs or that may identify pathways to target.
|
From page 75... ...
His research has historically focused on the development and application of statistical methods for the discovery and interpretation of genetic variation responsible for complex human disease, and with the recent creation of the ATGU, he and other core faculty are now focused on the interpretation of ge
|
From page 76... ...
While developing computational and statistical methods that can be broadly applied, his group has several primary medical genetics research foci. His lab serves as the analytic hub for the Psychiatric GWAS Consortium, an international consortium leading the largest collaborative GWAS studies in five major psychiatric disorders.
|
From page 77... ...
, as co-chair of the National Academies of Sciences, Engineering, and Medicine's Roundtable on Genomics and Precision Health, as a member of the advisory council for the National Center for Advancing Translational Sciences, as co-chair of the Cures Acceleration Network, as an advisor to the Pharmacogenetics Research Network, and as a member of the World Economic Forum's Global Agenda Council on the Future of the Health Sector.
|
From page 78... ...
She focuses on understanding the scientific and medical activities within the pancreatic cancer field and facilitating these activities through a grants program, a patient support program, and special research initiatives. Under her guidance, the grants program was expanded to include mechanisms focused on translational and clinical research activities, and the Know Your Tumor and patient-report outcomes registry initiatives were initiated.
|
From page 79... ...
Nadeem Sarwar, M.Pharm., M.R.Pharm.S., M.Phil., Ph.D., has expertise in human genetics-guided drug discovery and precision medicine. He has executive-level experience in academia (Tenured Faculty, University of Cambridge, United Kingdom)
|
From page 80... ...
The AiM Institute's exclusive mission is to realize human genetics driven drug discovery, with a predominant focus on delivering precision medicines for the subset of patients with immunedriven pathology in dementia (immunodementia) and oncology (immunooncology)
|
From page 81... ...
Genetics Core; sits on the National Academies of Sciences, Engineering, and Medicine's Roundtable on Genomics and Precision Health; serves on the Genetics Scientific Advisory Group of the European Prevention of Alzheimer's Disease Consortium; and facilitates the Industry Partnership for Human Genetics. Richard H
|
From page 82... ...
in molecular biology and genetics from Wayne State University School of Medicine in 1990. He was an NIH National Research Service Awards postdoctoral fellow in human genetics at the laboratory of Dr.
|
From page 83... ...
Most recently, he was the director of the National Cancer Institute's Cancer Genome Atlas Project and the Cancer Genome Atlas Program Office. David Wholley, M.Phil., manages the Research Partnerships Division of the Foundation for the National Institutes of Health, which is responsible for major research collaborations, including the Accelerating Medicines Partnership, the Biomarkers Consortium, the LungMAP precision medicine trial in lung cancer, and the Alzheimer's Disease Neuroimaging Initiative.
|
From page 84... ...
Mr. Wholley has held senior management roles in several venture-funded technology startup companies, including as head of global marketing and development for First Genetic Trust, Inc., which developed software for largescale collaborative genetic research and personalized medicine.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.